DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients

Information source: Verona Pharma plc
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Asthma

Intervention: RPL554 (Drug); Salbutamol (Drug); Placebo (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Verona Pharma plc

Official(s) and/or principal investigator(s):
Lief Bjermer, Principal Investigator, Affiliation: Skane University Hospital, Sweden
Johnston Stewart, Principal Investigator, Affiliation: Celerion, Northern Ireland

Overall contact:
Kenneth Newman, MD, Phone: +1 914 767 5007, Email: ken.newman@veronapharma.com


The number of people with of asthma and allergy is still increasing and a large number of patients still do not have their asthma well controlled. There is therefore a need for new asthma treatments that work well and have less side effects. The study compares a new experimental drug RPL554 with a marketed asthma drug (salbutamol) and placebo.

Clinical Details

Official title: A Phase II, Randomised, Double Blind, Placebo Controlled, Seven Way Crossover Study to Assess the Effect of Single Doses of RPL554 Compared to Salbutamol and Placebo Administered by Nebuliser on Lung Function of Patients With Chronic Asthma

Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Spirometry

Secondary outcome:


Systemic pharmacodynamic effect on blood pressure

Systemic pharmacodynamic effect on pulse rate

Systemic pharmacodynamic effect on ECG heart rate

Vital signs (Supine pulse rate)

Vital signs (Supine blood pressure)


Pharmacokinetics (AUC)

Pharmacokinetics (Cmax)

Pharmacokinetics (tmax)

Pharmacokinetics (half life)

Pharmacokinetics (MRT)

Detailed description: A seven way crossover study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled RPL554 compared to salbutamol and placebo in patients with mild to moderate chronic asthma. Salbutamol is a marketed beta-2 agonist typically used to treat bronchospasm (due to any cause, allergen asthma or exercise-induced), as well as chronic obstructive pulmonary disease but has associated dose-related systemic side effects. RPL554 is a dual PDE3 and PDE4 inhibitor that has bronchodilatory and anti-inflammatory actions and also the potential to stimulate increases in mucociliary clearance via its proven ability to activate CFTR. Four different doses of RPL554 will be compared with placebo and a two doses of salbutamol as benchmarks for bronchodilation and systemic side effects.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Provided written informed consent

- Males agree not to donate sperm and either be abstinent or use adequate

contraception. Females to be post-menopausal or surgically sterile

- Non-smoker or ex-smoker >6 months

- Diagnosed asthma for at least 6 months

- Pre-bronchodilator FEV1 ≥60% and ≤90% of predicted normal value and ≥1. 5 L at


- Increase in FEV1 of 15% within 30 minutes after a 2. 5mg dose of nebulised salbutamol

- Systolic blood pressure 90 to 145 mmHg, diastolic blood pressure 50 to 90 mmHg and

heart rate 45 to 80 beats per minute (bpm) after resting for 5 minutes in a supine position (average from two measurements)

- Capable of withdrawing from LABAs, LAMAs and SAMAs before screening and during study

and SABAs before screening and for 8 hours before each dose Exclusion Criteria:

- Asthma exacerbation in the last 3 months

- Any prior life threatening episode of asthma (intensive care admission)

- Any clinically significant disease or disorder or clinically relevant screening


- QTcF interval >450 ms or QT interval >500 ms or other abnormality in ECG

- History of ischemic heart disease or heart failure. History of recurrent or current

clinically significant arrhythmia or ECG abnormality as judged by the investigator

- Treatment with systemic glucocorticosteroids within 30 days before screening

- A suspected/manifested infection according to WHO risk classification 2, 3 or 4

Locations and Contacts

Kenneth Newman, MD, Phone: +1 914 767 5007, Email: ken.newman@veronapharma.com

Skane University Hospital, Lund, Sweden; Recruiting
Leif Bjermer
Leif Bjermer, Principal Investigator

Celerion, Belfast, United Kingdom; Recruiting
Johnston Stewart
Johnston Stewart, Principal Investigator

Additional Information

Starting date: April 2015
Last updated: May 23, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017